SRTS vs. STIM, SNWV, ZIMV, NVRO, TCMD, SKIN, NYXH, DRTS, ELMD, and RCEL
Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include Neuronetics (STIM), SANUWAVE Health (SNWV), ZimVie (ZIMV), Nevro (NVRO), Tactile Systems Technology (TCMD), Beauty Health (SKIN), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Electromed (ELMD), and AVITA Medical (RCEL). These companies are all part of the "medical equipment" industry.
Sensus Healthcare vs.
Neuronetics (NASDAQ:STIM) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
Sensus Healthcare received 58 more outperform votes than Neuronetics when rated by MarketBeat users. Likewise, 69.00% of users gave Sensus Healthcare an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.
Sensus Healthcare has a net margin of 15.90% compared to Neuronetics' net margin of -50.09%. Sensus Healthcare's return on equity of 12.60% beat Neuronetics' return on equity.
Sensus Healthcare has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Neuronetics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Neuronetics currently has a consensus target price of $5.50, suggesting a potential upside of 37.16%. Sensus Healthcare has a consensus target price of $11.67, suggesting a potential upside of 147.70%. Given Sensus Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Sensus Healthcare is more favorable than Neuronetics.
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by company insiders. Comparatively, 8.9% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Sensus Healthcare had 16 more articles in the media than Neuronetics. MarketBeat recorded 18 mentions for Sensus Healthcare and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.39 beat Sensus Healthcare's score of 0.10 indicating that Neuronetics is being referred to more favorably in the media.
Summary
Sensus Healthcare beats Neuronetics on 14 of the 19 factors compared between the two stocks.
Get Sensus Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensus Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:SRTS) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SRTS Stock Free SRTS Stock Alerts